Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...
Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ophthalmologists. Biosimilars may offer cost-effective alternatives, potentially ...
The market for TIGIT inhibitors is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with NSCLC, RCC, colorectal cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results